Market LIVE
Published markets; coverage varies by country
Product profile · United States

LATUDA

 ·  Patent Litigation & Settlement History ↓

IngredientLURASIDONE HYDROCHLORIDE
Application typeNDA
Application200603
Product004
Dosage formTABLET
RouteORAL
Strength120MG
Approval date2012-04-26
Marketing statusPrescription
Status event—
ApplicantSUNOVION PHARMS INC
Product source

Current GenericRadar decision

Year2019
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2019-01-03
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2019-01-03
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
87290852026-05-26DP ————
———
88837942026-05-26DP ————
———
95550272026-05-26DP/U U-543———
———
99077942026-05-26DP ————
———
87290852026-11-26— ————
—2026-11-26—
88837942026-11-26— ————
—2026-11-26—
99077942026-11-26— ————
—2026-11-26—
92594232031-05-23U U-1822———
———
98272422031-05-23U U-2201———
———
98272422031-05-23U U-2199———
———
92594232031-11-23— ————
—2031-11-23—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
207948 / 005APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——PAR PHARM INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208002 / 005FINAL_APPROVAL · FINAL_APPROVED2019-01-03—AMNEAL PHARMACEUTICALS CO GMBHNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208028 / 005FINAL_APPROVAL · FINAL_APPROVED2019-01-03—INVAGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208031 / 005FINAL_APPROVAL · FINAL_APPROVED2019-01-03—LUPIN LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208049 / 005FINAL_APPROVAL · FINAL_APPROVED2019-01-03—ACCORD HEALTHCARE INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208055 / 004FINAL_APPROVAL · FINAL_APPROVED2019-01-03—TORRENT PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208066 / 005FINAL_APPROVAL · FINAL_APPROVED2019-01-04—SUN PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208052 / 005FINAL_APPROVAL · FINAL_APPROVED2019-03-19—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208060 / 005FINAL_APPROVAL · FINAL_APPROVED2019-05-17—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212091 / 005FINAL_APPROVAL · FINAL_APPROVED2020-12-28—CHARTWELL RX SCIENCES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208016 / 005FINAL_APPROVAL · FINAL_APPROVED2021-02-02—WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213248 / 005FINAL_APPROVAL · FINAL_APPROVED2021-05-13—ALEMBIC PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208037 / 005FINAL_APPROVAL · FINAL_APPROVED2022-09-09—MSN LABORATORIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212244 / 005FINAL_APPROVAL · FINAL_APPROVED2022-12-13—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208058 / 005FINAL_APPROVAL · FINAL_APPROVED2023-02-28—HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208045 / 005FINAL_APPROVAL · FINAL_APPROVED2023-03-10—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212124 / 005FINAL_APPROVAL · FINAL_APPROVED2023-06-09—MACLEODS PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218174 / 005FINAL_APPROVAL · FINAL_APPROVED2024-08-21—ANNORA PHARMA PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210388 / 005FINAL_APPROVAL · FINAL_APPROVED2024-12-06—JUBILANT GENERICS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 18 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
208002 / 005AMNEAL PHARMACEUTICALS CO GMBHFINAL_APPROVAL · FINAL_APPROVED2019-01-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208028 / 005INVAGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2019-01-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208031 / 005LUPIN LTDFINAL_APPROVAL · FINAL_APPROVED2019-01-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208049 / 005ACCORD HEALTHCARE INCFINAL_APPROVAL · FINAL_APPROVED2019-01-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208055 / 004TORRENT PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2019-01-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208066 / 005SUN PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2019-01-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208052 / 005ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2019-03-19 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208060 / 005TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2019-05-17 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212091 / 005CHARTWELL RX SCIENCES LLCFINAL_APPROVAL · FINAL_APPROVED2020-12-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208016 / 005WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2021-02-02 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213248 / 005ALEMBIC PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2021-05-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208037 / 005MSN LABORATORIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2022-09-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212244 / 005ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2022-12-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208058 / 005HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INCFINAL_APPROVAL · FINAL_APPROVED2023-02-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208045 / 005AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2023-03-10 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212124 / 005MACLEODS PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2023-06-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218174 / 005ANNORA PHARMA PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2024-08-21 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210388 / 005JUBILANT GENERICS LTDFINAL_APPROVAL · FINAL_APPROVED2024-12-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2019-01-03TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.